Therapeutics

Capricor Therapeutics Faces Class Action Lawsuit as Investors Claim Misleading Statements Led to Financial Losses

by

Los Angeles, Calif. — A class action lawsuit has been initiated against Capricor Therapeutics, Inc. (CAPR) in response to claims that the company’s stock was sold at inflated prices. Filed by the law firm Levi & Korsinsky on July 17, 2025, the lawsuit alleges that shareholders purchased stock during a defined class period from October 9, 2024, to July 10, 2025, without full knowledge of the company’s actual financial condition. Affected investors are being encouraged to seek information on participation in the action. Capricor Therapeutics is engaged in the development of innovative cell and exosome-based … Read more

Investors Alert: Lead Plaintiff Opportunity in Intellia Therapeutics Securities Fraud Case Approaching Deadline

by

Investors in Intellia Therapeutics Inc., a leader in gene-editing technology, face a looming deadline to secure their position as lead plaintiffs in a securities fraud lawsuit alleging the company made misleading statements that adversely impacted shareholder values. The lawsuit, which is gaining momentum, centers around accusations that the Cambridge, Massachusetts-based biotech firm did not fully disclose operational and developmental setbacks during its recent trials, potentially violating federal securities laws. Originally filed in the United States District Court for the Northern District of California, the class-action suit represents investors who purchased shares in Intellia between May … Read more

Opportunity Opens for APLT Investors to Spearhead Securities Fraud Legal Action Against Applied Therapeutics, Inc.

by

Investors who have purchased shares of Applied Therapeutics, Inc. may have a significant opportunity to lead a securities fraud lawsuit against the biopharmaceutical company. Applied Therapeutics, based in New York, is currently under scrutiny for alleged misleading statements and possible fraudulent activities related to the success and regulatory status of its developmental drug candidates. The focus of the allegations centers on the company’s lead product candidate, AT-007, a central nervous system penetrant Aldose Reductase inhibitor being developed for the treatment of Galactosemia, a rare pediatric metabolic disease. Concerns were raised after discrepancies were noted between … Read more